Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Nordio

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Circulation|December 28, 2018
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48David D Berg, Christian T Ruff, Petr Jarolim, et al.
Environmental Health Perspectives|January 12, 2010
Exposure to metal-rich particulate matter modifies the expression of candidate microRNAs in peripheral blood leukocytesValentina Bollati, Barbara Marinelli, Pietro Apostoli, et al.
NPJ Vaccines|May 25, 2023
Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adultsInge LeFevre, Lulu Bravo, Nicolas Folschweiller, et al.
European Journal of Heart Failure|June 29, 2016
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48Giulia Magnani, Robert P Giugliano, Christian T Ruff, et al.
Thrombosis and Haemostasis|March 25, 2016
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 TrialEdward T Carreras, Willibald Hochholzer, Andrew L Frelinger, et al.
Environmental Health : a Global Access Science Source|August 11, 2010
Airborne particulate matter and mitochondrial damage: a cross-sectional studyLifang Hou, Zhong-Zheng Zhu, Xiao Zhang, et al.
The American Journal of Medicine|March 21, 2016
Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 TrialRobert P Giugliano, Christian T Ruff, Stephen D Wiviott, et al.
American Heart Journal|January 6, 2022
Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroupsBaris Gencer, Alon Eisen, David Berger, et al.
Circulation. Cardiovascular Quality and Outcomes|May 12, 2018
Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction)James Aisenberg, Prapti Chatterjee-Murphy, Kathryn Friedman Flack, et al.
American Heart Journal|February 10, 2016
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trialAlon Eisen, Robert P Giugliano, Christian T Ruff, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Circulation|December 28, 2018
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48David D Berg, Christian T Ruff, Petr Jarolim, et al.
Environmental Health Perspectives|January 12, 2010
Exposure to metal-rich particulate matter modifies the expression of candidate microRNAs in peripheral blood leukocytesValentina Bollati, Barbara Marinelli, Pietro Apostoli, et al.
NPJ Vaccines|May 25, 2023
Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adultsInge LeFevre, Lulu Bravo, Nicolas Folschweiller, et al.
European Journal of Heart Failure|June 29, 2016
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48Giulia Magnani, Robert P Giugliano, Christian T Ruff, et al.
Thrombosis and Haemostasis|March 25, 2016
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 TrialEdward T Carreras, Willibald Hochholzer, Andrew L Frelinger, et al.
Environmental Health : a Global Access Science Source|August 11, 2010
Airborne particulate matter and mitochondrial damage: a cross-sectional studyLifang Hou, Zhong-Zheng Zhu, Xiao Zhang, et al.
The American Journal of Medicine|March 21, 2016
Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 TrialRobert P Giugliano, Christian T Ruff, Stephen D Wiviott, et al.
American Heart Journal|January 6, 2022
Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroupsBaris Gencer, Alon Eisen, David Berger, et al.
Circulation. Cardiovascular Quality and Outcomes|May 12, 2018
Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction)James Aisenberg, Prapti Chatterjee-Murphy, Kathryn Friedman Flack, et al.
American Heart Journal|February 10, 2016
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trialAlon Eisen, Robert P Giugliano, Christian T Ruff, et al.
Pageof 6